Kimberley Jackson

2.9k total citations · 1 hit paper
28 papers, 2.1k citations indexed

About

Kimberley Jackson is a scholar working on Cellular and Molecular Neuroscience, Immunology and Molecular Biology. According to data from OpenAlex, Kimberley Jackson has authored 28 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 8 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Kimberley Jackson's work include Neuroscience and Neuropharmacology Research (6 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Pharmaceutical studies and practices (5 papers). Kimberley Jackson is often cited by papers focused on Neuroscience and Neuropharmacology Research (6 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Pharmaceutical studies and practices (5 papers). Kimberley Jackson collaborates with scholars based in United States, United Kingdom and Singapore. Kimberley Jackson's co-authors include Lu Zhang, Stephen L. Lowe, Ferenc Martényi, Darryle D. Schoepp, Bryan G. Johnson, Andreev Bv, Sergey Mosolov, Smulevich Ab, A M Reznik and James A. Monn and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Pain.

In The Last Decade

Kimberley Jackson

27 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

2007 790 citations Lu Zhang, Ferenc Martényi et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberley Jackson United States	16	882	882	333	265	197	28	2.1k
Christine A. Parker United Kingdom	24	900 1.0×	560 0.6×	128 0.4×	187 0.7×	314 1.6×	60	2.4k
William Charles Kreisl United States	26	841 1.0×	515 0.6×	190 0.6×	617 2.3×	497 2.5×	58	3.0k
Joseph B. Monahan United States	36	1.7k 1.9×	1.1k 1.2×	747 2.2×	100 0.4×	313 1.6×	76	3.4k
Sarjubhai A. Patel United States	14	860 1.0×	868 1.0×	63 0.2×	116 0.4×	142 0.7×	22	2.1k
Ming‐Lei Guo United States	31	1.3k 1.4×	574 0.7×	281 0.8×	44 0.2×	142 0.7×	91	2.9k
Qian Zhao China	28	638 0.7×	548 0.6×	110 0.3×	445 1.7×	105 0.5×	125	2.1k
Jun Wei China	31	1.8k 2.1×	238 0.3×	453 1.4×	185 0.7×	501 2.5×	169	3.6k
Orna Levran United States	32	1.8k 2.1×	751 0.9×	70 0.2×	133 0.5×	185 0.9×	75	3.4k
Nancy L. Reichenbach United States	27	737 0.8×	257 0.3×	252 0.8×	225 0.8×	189 1.0×	54	2.1k
Lars Tönges Germany	34	1.5k 1.6×	1.1k 1.3×	123 0.4×	115 0.4×	89 0.5×	115	3.7k

Countries citing papers authored by Kimberley Jackson

Since Specialization

Citations

This map shows the geographic impact of Kimberley Jackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberley Jackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberley Jackson more than expected).

Fields of papers citing papers by Kimberley Jackson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberley Jackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberley Jackson. The network helps show where Kimberley Jackson may publish in the future.

Co-authorship network of co-authors of Kimberley Jackson

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberley Jackson. A scholar is included among the top collaborators of Kimberley Jackson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberley Jackson. Kimberley Jackson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilbraham, Darren, Haitao Zhao, Kimberley Jackson, et al.. (2024). Clinical proof-of-concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states. Pain. 166(7). 1497–1518. 3 indexed citations

Datta‐Mannan, Amita, Wen Xu, Kimberley Jackson, et al.. (2024). Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study. Clinical Therapeutics. 47(1). 55–61.

Zheng, Min, Kimberley Jackson, Fan Yang, et al.. (2023). Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study. Advances in Therapy. 40(9). 3804–3816. 2 indexed citations

Felder, Christian C., Paul Goldsmith, Kimberley Jackson, et al.. (2018). Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology. 136(Pt C). 449–458. 64 indexed citations

Reich, Kristian, Kimberley Jackson, Susan Ball, et al.. (2018). Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. Journal of Investigative Dermatology. 138(10). 2168–2173. 39 indexed citations

Mehta, Mitul A., Anne Schmechtig, Juliet McColm, et al.. (2018). Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. Psychopharmacology. 235(7). 1875–1886. 31 indexed citations

Gómez, Elisa, et al.. (2017). Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. BioDrugs. 31(6). 545–554. 33 indexed citations

Duffin, Kristina Callis, Jerry Bagel, Michael Bukhalo, et al.. (2016). Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A). Journal of the European Academy of Dermatology and Venereology. 31(1). 107–113. 35 indexed citations

Lowe, Stephen L., Emanuele Sher, Graham N. Wishart, et al.. (2016). An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs. Drug Delivery and Translational Research. 7(1). 11–15. 8 indexed citations

10.

Gray, Jhanelle E., Jeffrey R. Infante, Les Brail, et al.. (2015). A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. 33(6). 1187–1196. 59 indexed citations

11.

Post, Anke, Trevor Smart, Gerard R. Dawson, et al.. (2015). A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology. 41(7). 1803–1812. 82 indexed citations

12.

Mendizábal, Nieves Vélez de, Kimberley Jackson, Brian J. Eastwood, et al.. (2015). A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats. Journal of Pharmacokinetics and Pharmacodynamics. 42(6). 721–733. 5 indexed citations

13.

Zamek‐Gliszczynski, Maciej J., Trent L. Abraham, Palaniappan Kulanthaivel, et al.. (2013). Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure. Drug Metabolism and Disposition. 41(4). 714–726. 36 indexed citations

14.

Lapteva, Natalia, April Durett, Jiali Sun, et al.. (2012). Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 14(9). 1131–1143. 171 indexed citations

15.

Kinon, Bruce J., Lu Zhang, Brian A. Millen, et al.. (2011). A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia. Journal of Clinical Psychopharmacology. 31(3). 349–355. 190 indexed citations

16.

Lowe, Stephen L., Robert A. Dean, Bradley L. Ackermann, et al.. (2011). Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology. 219(4). 959–970. 9 indexed citations

17.

Gueorguieva, Ivelina, Kimberley Jackson, Steven Wrighton, Vikram Sinha, & Jenny Y. Chien. (2010). Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials. British Journal of Clinical Pharmacology. 70(4). 523–536. 11 indexed citations

18.

Zhang, Lu, Ferenc Martényi, Stephen L. Lowe, et al.. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine. 13(9). 1102–1107. 790 indexed citations breakdown →

19.

Zeiher, Bernhardt, Antonio Artigas, Jean‐Louis Vincent, et al.. (2004). Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Critical Care Medicine. 32(8). 1695–1702. 246 indexed citations

20.

Jackson, Kimberley & Sara Rosenbaum. (1998). The Application of Population Pharmacokinetics to the Drug Development Process. Drug Development and Industrial Pharmacy. 24(12). 1155–1162. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact